Skip to main
TRAX

TRAX Stock Forecast & Price Target

TRAX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

First Tracks is expected to have strong financials with a positive outlook as it anticipates its FDA Fast Track Designation for ANB033 to be a success. With the company's unique approach and strong pipeline, the positive results from its clinical trials and potential regulatory approvals, we expect strong financial growth and potential for significant future revenue. However, there are potential risks such as safety concerns or competition from other treatments, which could impact the company's success.

Bears say

First Tracks is an early-stage biotechnology company with a narrow focus on immunology therapeutics, limiting its potential market and revenue opportunities. The company also faces stiff competition from established pharmaceutical companies and regulatory hurdles in getting its drugs to market. Additionally, the company's financials show a negative trend, with increasing losses and decreasing cash reserves, indicating potential financial instability in the future.

TRAX has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast

Analysts have given TRAX a Buy based on their latest research and market trends.

According to 8 analysts, TRAX has a Buy consensus rating as of Aug 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

First Tracks Biotherapeutics Inc (TRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.